Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ERAS | INST-CLUSTER | bullish | 6/10 | 17 institutions accumulated $24.5M in Erasca (ERAS) during 2024-Q3 (net +$9.8M vs. Q2), led by Citadel, Dimensional Fund | Jun 12, 2026 |
| GSK | 6-K | bullish | 5/10 | GSK announced that momelotinib received Orphan Drug Designation (ODD) from the FDA and EMA for VEXAS syndrome, a rare li | Jun 12, 2026 |
| IVA | 6-K | neutral | 3/10 | Inventiva S.A. filed a notice for its Ordinary and Extraordinary General Meeting on June 30, 2026, with 40 resolutions c | Jun 12, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED presented Phase III ESLIM-02 data for sovleplenib in wAIHA at EHA 2026, showing a 66% durable response rate vs | Jun 12, 2026 |
| ATHE | 6-K | neutral | 3/10 | Alterity Therapeutics completed a 50-to-1 reverse stock split, reducing outstanding ordinary shares to 217,508,862. The | Jun 12, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH in hypoparathyroid | Jun 12, 2026 |
| CXXIF | 6-K | mixed | 5/10 | C21 Investments reported FY2026 results with revenue of $32.6M (+8.3% YoY), operating income of $2.3M (+78% YoY), and Ad | Jun 12, 2026 |
| SCLX | EFFECT | bearish | 6/10 | Scilex Holding Co's S-3 shelf registration (File No. 333-296430) became effective on June 11, 2026. This allows the comp | Jun 12, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platf | Jun 12, 2026 |
| CHRS | INST-CLUSTER | bearish | 4/10 | In Q3 2024, a small group of asset managers increased CHRS holdings by $795K, while Temasek Holdings fully exited a $10. | Jun 12, 2026 |
| NTHI | 8-K | bearish | 6/10 | NeOnc Technologies raised $5M via a private placement of Series A Convertible Preferred Stock at $833.34/share (stated v | Jun 12, 2026 |
| CGON | INST-CLUSTER | bullish | 6/10 | A significant institutional cluster formed in CG Oncology during Q3 2024, with 14 buyers accumulating $41.7M in net new | Jun 12, 2026 |
| BMEA | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster in BMEA for Q3 2024 shows 6 buyers (net +$2.9M) led by Marshall Wace doubling its stake to | Jun 12, 2026 |
| SYRE | INST-CLUSTER | bullish | 6/10 | A major institutional cluster reveals 13 net buyers vs 3 net sellers in SYRE during Q3 2024, with aggregate buying of $8 | Jun 12, 2026 |
| AUTL | PRESS-RELEASE | neutral | 3/10 | Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a prestigious industry recog | Jun 12, 2026 |
| ALXO | INST-CLUSTER | bearish | 5/10 | A mixed institutional cluster in ALXO for Q3 2024 shows 6 buyers (net +$124K) and 4 sellers (net -$3.74M), dominated by | Jun 12, 2026 |
| XERS | INST-CLUSTER | bullish | 4/10 | Six institutional buyers accumulated $3.5M in XERS shares during 2024-Q3, led by quant hedge fund D.E. Shaw which added | Jun 12, 2026 |
| ABUS | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster in ABUS for Q3 2024 shows 6 buyers (net +$6.2M) led by Schwab and Citadel doubling their p | Jun 12, 2026 |
| CATX | INST-CLUSTER | bullish | 5/10 | A significant institutional cluster formed in CATX during Q3 2024, with 8 buyers accumulating $13.3M in net new position | Jun 12, 2026 |
| LXRX | INST-CLUSTER | bearish | 5/10 | A mixed institutional cluster emerged in LXRX during Q3 2024: four asset managers (led by Legal & General Group doubling | Jun 12, 2026 |
| LXEO | INST-CLUSTER | bullish | 5/10 | A cluster of 8 institutional buyers accumulated positions in Lexeo Therapeutics during Q3 2024, led by Blackstone (addin | Jun 12, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While th | Jun 12, 2026 |
| AXSM | CLUSTER | neutral | 4/10 | A cluster of insider sales at Axsome Therapeutics (AXSM) over the past week totaled ~$20.2M in open-market transactions, | Jun 11, 2026 |
| HOWL | CLUSTER | bearish | 5/10 | Two insiders at Werewolf Therapeutics, a director and a 10% owner, sold a total of ~$156K in open-market sales over two | Jun 11, 2026 |
| RKDA | PRESS-RELEASE | bearish | 7/10 | Arcadia Biosciences announces a private placement of ~3.88M common shares (or pre-funded warrants) plus two series of pr | Jun 11, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs | Jun 11, 2026 |
| NATR | CLUSTER | neutral | 4/10 | Two regional EVP Presidents at Nature's Sunshine sold shares totaling $439K (0.12% of market cap) in open-market transac | Jun 11, 2026 |
| CUE | 3 | neutral | 2/10 | Sumita Ray filed a Form 3 initial statement of beneficial ownership after becoming Chief Legal Compliance Officer and Co | Jun 11, 2026 |
| TNGX | 144 | neutral | 2/10 | Officer Daniella Beckman filed a Form 144 notice of intent to sell 4,446 shares of TNGX common stock, with an estimated | Jun 11, 2026 |
| VSTM | INST-CLUSTER | bullish | 5/10 | Seven institutional investors accumulated $4.2M net in Verastem (VSTM) in Q3 2024, led by Alyeska Investment Group more | Jun 11, 2026 |